Novartis AG (NYSE:NVS)
| 89.85 Delayed Data As of Jan 26 |  +0.01 / +0.01%Today’s Change | 74.09 Today|||52-Week Range 94.26 | -0.96% Year-to-Date |
Latest NVS News | Press Releases
| Is a Beat on the Cards for Novo Nordisk (NVO) in Q4 Earnings? Jan 26 / Zacks.com - Paid Partner Content | The Zacks Analyst Blog Highlights Nike, Novartis, Wells Fargo, Broadcom and Anheuser-Busch Jan 18 / Zacks.com - Paid Partner Content |
| Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine Jan 24 / Zacks.com - Paid Partner Content | Top Stock Reports for NIKE, Novartis & Wells Fargo Jan 17 / Zacks.com - Paid Partner Content |
| How to Find Strong Medical Stocks Slated for Positive Earnings Surprises Jan 23 / Zacks.com - Paid Partner Content | Incyte (INCY) Up 7% in a Year: Will the Momentum Continue? Jan 17 / Zacks.com - Paid Partner Content |
| Top 5 4th Quarter Trades of Veriti Management LLC Jan 20 / GuruFocus News - Paid Partner Content |
Today’s Trading
| Previous close | 89.84 |
| Today’s open | 91.03 |
| Day’s range | 89.42 - 91.08 |
| Volume | 87 |
| Average volume (3 months) | 2,187,035 |
| Market cap | $198.4B |
Data as of 4:00pm ET, 01/26/2023
Growth & Valuation
| Earnings growth (last year) | +202.15% |
| Earnings growth (this year) | -4.51% |
| Earnings growth (next 5 years) | +4.53% |
| Revenue growth (last year) | +6.10% |
| P/E ratio | 9.3 |
| Price/Sales | 3.83 |
| Price/Book | 3.03 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AZNAstraZeneca | -0.64 | -0.96% |
| NVONovo Nordisk | -0.10 | -0.07% |
| BMYBristol-Myers Squibb | -0.01 | -0.01% |
| PFEPfizer | +0.01 | +0.02% |
Data as of 4:00pm ET, 01/26/2023
Financials
| Next reporting date | February 1, 2023 |
| EPS forecast (this quarter) | $1.40 |
| Annual revenue (last year) | $51.6B |
| Annual profit (last year) | $24.0B |
| Net profit margin | 46.53% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Basel, Basel-stadt (basle Town) |
Forecasts
